In Figure 2 of the article “Gleason Score at Diagnosis Predicts the Rate of Detection of 18F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients,” by Cimitan et al. (J Nucl Med. 2015;56:209–215), the reported sensitivities for serum prostate-specific antigen are incorrect. The correct sensitivities are 58.4%, 79.5%, 84.2%, and 89.8% for prostate-specific antigen levels of 1.00, 1.50, 2.00, and 5.00 ng/mL, respectively. The authors regret the error.
- © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
